The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
DKK 2016 | Factors that contribute to treatment decisions in acute myeloid leukemia
Christoph Röllig
• 25 Feb 2016
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains the different therapeutic needs of patients with acute myeloid leukemia, which is recognised as a clinically heterogeneous disease.
